BMO Raises Eli Lilly Price Target to $1,650, Keeps Outperform Rating
BMO raised its price target on Eli Lilly to $1,650 from $1,400 and maintained its Outperform rating.
BMO raised its price target on Eli Lilly to $1,650 from $1,400 and maintained its Outperform rating.